Pharming Group Nv Stock Retained Earnings
| PHGUF Stock | USD 0.90 0.11 13.92% |
Pharming Group NV fundamentals help investors to digest information that contributes to Pharming Group's financial success or failures. It also enables traders to predict the movement of Pharming Pink Sheet. The fundamental analysis module provides a way to measure Pharming Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharming Group pink sheet.
Pharming |
Pharming Group NV Company Retained Earnings Analysis
Pharming Group's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Pharming Group Retained Earnings | (273 M) |
Most of Pharming Group's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharming Group NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Pharming Group NV has a Retained Earnings of (273 Million). This is 129.31% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The retained earnings for all United States stocks is 102.93% higher than that of the company.
Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
Pharming Fundamentals
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0643 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 721.19 M | |||
| Shares Outstanding | 652.41 M | |||
| Shares Owned By Insiders | 1.97 % | |||
| Shares Owned By Institutions | 16.43 % | |||
| Price To Earning | 18.97 X | |||
| Price To Book | 3.94 X | |||
| Price To Sales | 3.69 X | |||
| Revenue | 167.68 M | |||
| Gross Profit | 177.73 M | |||
| EBITDA | 41.22 M | |||
| Net Income | 16 M | |||
| Cash And Equivalents | 189.96 M | |||
| Cash Per Share | 0.29 X | |||
| Total Debt | 122.65 M | |||
| Debt To Equity | 0.75 % | |||
| Current Ratio | 5.22 X | |||
| Book Value Per Share | 0.30 X | |||
| Cash Flow From Operations | 37.84 M | |||
| Earnings Per Share | 0.05 X | |||
| Target Price | 24.89 | |||
| Number Of Employees | 277 | |||
| Beta | 0.98 | |||
| Market Capitalization | 880.76 M | |||
| Total Asset | 350.55 M | |||
| Retained Earnings | (273 M) | |||
| Working Capital | 23 M | |||
| Current Asset | 41 M | |||
| Current Liabilities | 18 M | |||
| Z Score | 4.2 | |||
| Net Asset | 350.55 M |
About Pharming Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharming Group NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Pharming Pink Sheet
When determining whether Pharming Group NV is a strong investment it is important to analyze Pharming Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pharming Group's future performance. For an informed investment choice regarding Pharming Pink Sheet, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..